Similarly, sEH inhibitors have been shown to reduce alloydynia in mice models of STZ-induced diabetic neuropathy, with results better than celecoxib without the adverse effects associated with COX inhibitors [30,31]. The gene discussed is EPHX2; the disease is diabetic neuropathy.